Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Acquisitions (2017 - 2021)

Aytu Biopharma (AYTU) has disclosed Acquisitions for 5 consecutive years, with $15.4 million as the latest value for Q1 2021.

  • Quarterly Acquisitions changed N/A to $15.4 million in Q1 2021 from the year-ago period, while the trailing twelve-month figure was $72393.0 through Jun 2021, changed 0.0% year-over-year, with the annual reading at $15.7 million for FY2021, 168.75% up from the prior year.
  • Acquisitions for Q1 2021 was $15.4 million at Aytu Biopharma, up from $5.5 million in the prior quarter.
  • The five-year high for Acquisitions was $15.4 million in Q1 2021, with the low at -$5.4 million in Q2 2017.
  • Average Acquisitions over 3 years is $5.2 million, with a median of $5.5 million recorded in 2020.